Daiichi Sankyo Launched Oxycodone Extended Release Tablets NX “Daiichi Sankyo” in Japan

| By | Daiichi Sankyo, Generics, Japan
0
124

Daiichi Sankyo Company Limited announced it has launched a new generic formulation of oxycodone hydrochloride hydrate extended release tablets for sustained cancer pain treatment in Japan: Oxycodone Extended Release Tablets 5 mg, 10 mg, 20 mg and 40 mg NX “Daiichi Sankyo”.

The new formulation of oxycodone hydrochloride, a strong opioid analgesic providing relief of moderate to severe pain in various types of cancer, contains the narcotic antagonist naloxone in order to prevent abuse.

It is manufactured from drug substance to formulation solely by Daiichi Sankyo’s subsidiary in Japan, Daiichi Sankyo Propharma Co., Ltd. (marketing authorization holder).

The addition of the new formulation to our product lineup of opioid analgesics will provide another treatment option to patients suffering from cancer pain and further enhance our contribution to healthcare in Japan.

Product Name

Therapeutic

Category

Original Brand Name

Oxycodone Extended Release Tablets 5mg NX “Daiichi Sankyo”

Oxycodone Extended Release Tablets 10mg NX “Daiichi Sankyo”

Oxycodone Extended Release Tablets 20mg NX “Daiichi Sankyo”

Oxycodone Extended Release Tablets 40mg NX “Daiichi Sankyo”

Sustained cancer

pain treatment

OxyContin® TR Tablets 5 mg

OxyContin® TR Tablets 10 mg

OxyContin® TR Tablets 20 mg

OxyContin® TR Tablets 40 mg

SOURCE: daiichisankyo.com
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.